Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

3-YEARS and Beyond Study Completion Results of the Otpkima Randomized Clinical Trial in Elderly CML Patients

Blood (2023) 142 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2023-177619

Published: 2023

Journal Articles

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Younger Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Blood (2023) 142 (Supplement 1): 1811.

https://doi.org/10.1182/blood-2023-188934

Published: 2023

Journal Articles

Efficacy of Frontline Treatment with Initial Low-Dose Tyrosine-Kinase Inhibitors in Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Blood (2023) 142 (Supplement 1): 3176.

https://doi.org/10.1182/blood-2023-186406

Published: 2023

Journal Articles

Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A "Campus CML" Study

Blood (2022) 140 (Supplement 1): 3906–3907.

https://doi.org/10.1182/blood-2022-170415

Published: 2022

Journal Articles

Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)

Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Alessandra Iurlo, Valerio De Stefano, Marta Anna Sobas, Elisa Rumi, Elena Maria Elli, Francesca Lunghi, Mercedes Gasior Kabat, Beatriz Cuevas, Paola Guglielmelli, Massimiliano Bonifacio, Monia Marchetti, Alberto Alvarez-Larran, Laura Maria Fox, Marta Bellini, Rosa Daffini, Giulia Benevolo, Gonzalo Carreño, Andrea Patriarca, Haifa Kathrin Al-Ali, Marcio Andrade, Francesca Palandri, Claire Harrison, Maria Angeles Foncillas, Santiago Osorio, Steffen Koschmieder, Elena Magro, Jean-Jacques Kiladjian, Estefanía Bolaños, Florian H. Heidel, Keina Quiroz, Martin Griesshammer, Valentín García Gutiérrez, Alberto Marin Sanchez, Juan Carlos Hernandez Boluda, Emma Lopez Abadia, Giuseppe Carli, Miguel Sagüés, Rajko Kusec, Blanca Xicoy, Margarita Guenova, Begoña Navas, Anna Angona, Edyta Cichocka, Anna Masternak, Daniele Cattaneo, Cristina Bucelli, Silvia Betti, Oscar Borsani, Fabrizio Cavalca, Sara Carbonell, Natalia Curto-Garcia, Lina Benajiba, Alessandro Rambaldi, Alessandro M. Vannucchi

Blood (2022) 140 (Supplement 1): 6815–6818.

https://doi.org/10.1182/blood-2022-158902

Published: 2022

Journal Articles

Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study

Blood (2022) 140 (Supplement 1): 1504–1506.

https://doi.org/10.1182/blood-2022-162207

Published: 2022

Journal Articles

Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial

Blood (2022) 140 (Supplement 1): 1797–1799.

https://doi.org/10.1182/blood-2022-157255

Published: 2022

Journal Articles

Use of Defibrotide in Patients with COVID-19 Pneumonia; Results of the Defi-VID19 Phase 2 Trial

Blood (2021) 138 (Supplement 1): 672.

https://doi.org/10.1182/blood-2021-147784

Published: 2021

Journal Articles

Risk of Progression in Chronic Phase - Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO study): Preliminary Results

Sarit Assouline, Maria Cristina Miggiano, Elisabetta Abruzzese, Chiara Elena, Giovanni Caocci, Susanne Saussele, Francesca Lunghi, Alberto Alvarez-Larran, Barbara Mora, Sigi Petrela, Laura Antolini, Carlo Gambacorti-Passerini, Alessandra Iurlo

Blood (2021) 138 (Supplement 1): 1476.

https://doi.org/10.1182/blood-2021-150496

Published: 2021

Journal Articles

Second Versus First Wave of COVID-19 in Patients with MPN

Tiziano Barbui, Alessandra Iurlo, Arianna Masciulli, Alessandra Carobbio, Arianna Ghirardi, Greta Carioli, Marta Sobas, Elena Maria Elli, Elisa Rumi, Valerio De Stefano, Francesca Lunghi, Monia Marchetti, Rosa Daffini, Mercedes Gasior Kabat, Beatriz Cuevas, Laura Maria Fox, Marcio Andrade, Francesca Palandri, Paola Guglielmelli, Giulia Benevolo, Claire N. Harrison, Maria Angeles Foncillas, Massimiliano Bonifacio, Alberto Alvarez-Larran, Jean-Jacques Kiladjian, Estefanía Bolaños, Andrea Patriarca, Keina Quiroz, Martin Griesshammer, Valentín Garcia Gutierrez, Alberto Marin Sanchez, Elena Magro, Marco Ruggeri, Juan Carlos Hernandez Boluda, Santiago Osorio, Gonzalo Carreño Gomez-Tarragona, Miguel Sagüés, Rajko Kusec, Begoña Navas, Anna Angona, Blanca Xicoy, Emma Lopez Abadia, Steffen Koschmieder, Daniele Cattaneo, Cristina Bucelli, Edyta Cichocka, Anna Masternak, Fabrizio Cavalca, Oscar Borsani, Silvia Betti, Marta Bellini, Natalia Curto-Garcia, Alessandro Rambaldi, Alessandro Vannucchi

Blood (2021) 138 (Supplement 1): 315.

https://doi.org/10.1182/blood-2021-146134

Published: 2021

Journal Articles

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

Simona Soverini, Luana Bavaro, Caterina De Benedittis, Margherita Martelli, Alessandra Iurlo, Nicola Orofino, Simona Sica, Federica Sorà, Francesca Lunghi, Fabio Ciceri, Sara Galimberti, Claudia Baratè, Massimiliano Bonifacio, Luigi Scaffidi, Fausto Castagnetti, Gabriele Gugliotta, Francesco Albano, Antonella Vita Russo Rossi, Fabio Stagno, Francesco di Raimondo, Mariella D’Adda, Eros di Bona, Elisabetta Abruzzese, Gianni Binotto, Rosaria Sancetta, Marzia Salvucci, Isabella Capodanno, Mariella Girasoli, Sabrina Coluzzi, Immacolata Attolico, Caterina Musolino, Elisabetta Calistri, Mario Annunziata, Monica Bocchia, Stefania Stella, Anna Serra, Santa Errichiello, Giuseppe Saglio, Fabrizio Pane, Paolo Vigneri, Flavio Mignone, Maria Antonella Laginestra, Stefano Aldo Pileri, Antonio Percesepe, Elena Tenti, Gianantonio Rosti, Michele Baccarani, Michele Cavo, Giovanni Martinelli

Blood (2020) 135 (8): 534–541.

https://doi.org/10.1182/blood.2019002969

Published: 2020

Includes: Supplemental data

Journal Articles

Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study

Blood (2020) 135 (5): 381–386.

https://doi.org/10.1182/blood.2019002614

Published: 2020

Includes: Supplemental data

Journal Articles

Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making

Blood (2019) 134 (Supplement_1): 661.

https://doi.org/10.1182/blood-2019-126767

Published: 2019

Journal Articles

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation

Blood (2019) 134 (Supplement_1): 4153.

https://doi.org/10.1182/blood-2019-129335

Published: 2019

Journal Articles

Dose Optimization in Elderly CML Patients Treated with Bosutinib after Intolerance or Failure of First-Line Tyrosine Kinase Inhibitors

Blood (2019) 134 (Supplement_1): 496.

https://doi.org/10.1182/blood-2019-127514

Published: 2019

Journal Articles

Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls

Valerio De Stefano, MD, Arianna Ghirardi, PhD, Arianna Masciulli, PhD, Alessandra Carobbio, BSc, Francesca Palandri, PhD MD, Nicola Vianelli, MD, Elena Rossi, MD PhD, Silvia Betti, MD PhD, Ambra Di Veroli, MD, Alessandra Iurlo, MD PhD, Daniele Cattaneo, MD, Guido Finazzi, MD, Massimiliano Bonifacio, MD, Luigi Scaffidi, MD, Andrea Patriarca, MD, Elisa Rumi, MD, Ilaria Carola Casetti, MD, Clemency Stephenson, MD, Paola Guglielmelli, MD PhD, Elena Maria Elli, MD, Miroslava Palova, MD, Davide Rapezzi, MD, Daniel Erez, MD, Montse Gomez, MD, Kai Wille, MD, Manuel Pérez-Encinas, MD, Francesca Lunghi, MD, Anna Angona, MD PhD, Maria Laura Fox, MD, Eloise Beggiato, MD, Giulia Benevolo, MD, Giuseppe Carli, MD, Rossella Rosaria Cacciola, MD, Mary Frances McMullin, MD FRCPath, FRCP, Alessia Tieghi, MD, Valle Recasens, MD, Monia Marchetti, MD, Martin Griesshammer, MD, Alberto Alvarez-Larrán, MD PhD, Alessandro M. Vannucchi, MD, Alessandro Rambaldi, MD PhD, Tiziano Barbui, MD

Blood (2019) 134 (Supplement_1): 4170.

https://doi.org/10.1182/blood-2019-127982

Published: 2019

Journal Articles

Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing

Simona Soverini, PhD, Luana Bavaro, Margherita Martelli, Caterina De Benedittis, PhD, Alessandra Iurlo, Nicola Orofino, MD, Livio Pagano, Marianna Criscuolo, Massimiliano Bonifacio, Luigi Scaffidi, MD, Simona Sica, MD, Federica Sorà, MD, Elena Maino, Michela Rondoni, MD, Maria Antonella Laginestra, PhD, Francesca Lunghi, Anna Ermacora, Mariella D'adda, MD, Gabriele Gugliotta, MD PhD, Fausto Castagnetti, Gianantonio Rosti, Cristina Papayannidis, Giovanni Marconi, Antonio Curti, Maria Cristina Miggiano, Sara Galimberti, Antonio Percesepe, MD PhD, Fabio Stagno, Rosaria Sancetta, MD, Mario Annunziata, Franca Falzetti, MD, Isabella Capodanno, Patrizia Pregno, Margherita Maffioli, MD, Tamara Intermesoli, MD, Eros Di Bona, MD, Giovanni Caocci, MD, Imma Attolico, MD, Gianni Binotto, Monica Bocchia, MD PhD, Emanuele Angelucci, MD, Nicola Sgherza, MD, Luigiana Luciano, Flavio Mignone, Stefano A. Pileri, MD PhD, Giovanni Martinelli, Michele Cavo, MD

Blood (2018) 132 (Supplement 1): 789.

https://doi.org/10.1182/blood-2018-99-117166

Published: 2018

Journal Articles

First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response

Blood (2018) 132 (Supplement 1): 4251.

https://doi.org/10.1182/blood-2018-99-110250

Published: 2018

Journal Articles

Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms

Tiziano Barbui, MD, Arianna Ghirardi, PhD, Arianna Masciulli, PhD, Alessandra Carobbio, MSc, Francesca Palandri, PhD MD, Nicola Vianelli, MD, Valerio De Stefano, MD, Silvia Betti, MD, Ambra Di Veroli, MD, Alessandra Iurlo, Daniele Cattaneo, MD, Federica Delaini, MSc, Massimiliano Bonifacio, MD, Luigi Scaffidi, MD, Andrea Patriarca, MD, Elisa Rumi, MD, Clemency Stephenson, MD, Paola Guglielmelli, MD PhD, Elena Maria Elli, MD, Palova Miroslava, MD, Laura Bertolotti, MSc, Daniel Erez, MD, Montse Gomez, MD, Kai Wille, MD, Manuel Pérez-Encinas, MD, Francesca Lunghi, Anna Angola Figueras, MD, Maria Laura Fox, MD, Eloise Beggiato, MD, Giulia Benevolo, MD, Giuseppe Carli, MD, Rossella Rosari Cacciola, Mary Frances McMullin, MD, Alessia Tieghi, MD, Valle Recanses Flores, MD, Monia Marchetti, Martin Griesshammer, MD PhD, Alberto Alvarez-Larran, MD, Alessandro M. Vannucchi, MD, Guido Finazzi, MD

Blood (2018) 132 (Supplement 1): 4279.

https://doi.org/10.1182/blood-2018-99-112387

Published: 2018

Journal Articles

Immune Reconstitution Is a Predictive Biomarker of Chronic Graft-Versus-Host Disease: Analysis of 307 Consecutive Patients

Blood (2018) 132 (Supplement 1): 4579.

https://doi.org/10.1182/blood-2018-99-113855

Published: 2018

NARROW

3-YEARS and Beyond Study Completion Results of the Otpkima Randomized Clinical Trial in Elderly CML Patients

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Younger Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Efficacy of Frontline Treatment with Initial Low-Dose Tyrosine-Kinase Inhibitors in Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A "Campus CML" Study

Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)

Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study

Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial

Use of Defibrotide in Patients with COVID-19 Pneumonia; Results of the Defi-VID19 Phase 2 Trial

Risk of Progression in Chronic Phase - Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO study): Preliminary Results

Second Versus First Wave of COVID-19 in Patients with MPN

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study

Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation

Dose Optimization in Elderly CML Patients Treated with Bosutinib after Intolerance or Failure of First-Line Tyrosine Kinase Inhibitors

Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls

Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing

First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response

Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms

Immune Reconstitution Is a Predictive Biomarker of Chronic Graft-Versus-Host Disease: Analysis of 307 Consecutive Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only